Ganglion Thickness
Introduction
Background
A ganglion (plural: ganglia) is a cluster of nerve cell bodies located in the peripheral nervous system. These structures serve as relay stations and integration centers for nerve signals, processing information and transmitting it between different parts of the nervous system. Ganglion thickness refers to the physical dimension or size of these nerve clusters. Like other anatomical features, the precise size and morphology of ganglia can vary significantly among individuals, influenced by a multitude of factors.
Biological Basis
The thickness of a ganglion is determined by the number and size of its constituent neurons, the density of associated glial cells (which provide support and protection), and the amount of connective tissue encapsulating it. These cellular and structural components are under complex biological regulation. Genetic factors are believed to play a role in modulating cellular proliferation, differentiation, and tissue development within the nervous system, thereby influencing the ultimate dimensions of ganglia. Environmental factors, such as injury, inflammation, or disease processes, can also contribute to changes in ganglion size and morphology.
Clinical Relevance
Variations or abnormalities in ganglion thickness can have significant clinical implications. For instance, an enlarged ganglion might indicate inflammation, nerve compression (such as in carpal tunnel syndrome if referring to specific wrist ganglia, or spinal nerve root compression), or the presence of a tumor. Such conditions can lead to symptoms like pain, sensory disturbances (numbness, tingling), or motor deficits, depending on the ganglion's location and the nerves it affects. Conversely, reduced ganglion thickness could be associated with neurodegenerative processes or nerve atrophy. Measuring ganglion thickness, often through advanced imaging techniques, can be a valuable diagnostic tool for clinicians to identify underlying neurological conditions, monitor disease progression, and guide appropriate therapeutic interventions.
Social Importance
Understanding the factors that influence ganglion thickness contributes to a broader comprehension of nervous system health and disease. From a public health perspective, identifying genetic predispositions to abnormal ganglion dimensions could lead to earlier diagnosis and preventative strategies for associated neurological conditions. Research into the biological mechanisms governing ganglion size may also unlock new therapeutic targets for neuropathies, chronic pain syndromes, and other neurological disorders, ultimately improving the quality of life for affected individuals and reducing the burden of these conditions on healthcare systems.
Population Specificity and Generalizability
A significant limitation in current genetic studies of ganglion thickness is the restricted diversity of study populations. Many analyses, for instance, have been primarily conducted within cohorts of white participants, which limits the generalizability of the findings to other ethnic groups. [1] This demographic bias means that identified genetic variants and their associations may not be transferable, and crucial population-specific variants or different effect sizes may be missed in underrepresented groups. [1] Further research in diverse populations is essential to assess the broader applicability of these genetic insights and to uncover additional variants that contribute to ganglion thickness across the global population.
Beyond ethnic homogeneity, cohorts can also present specific biases, such as being on the younger and healthier end of the spectrum, which may affect the generalizability of findings to older or less healthy populations. [2] Population differences, extending beyond ethnicity to include variations in age ranges or environmental exposures between cohorts, can introduce heterogeneity in meta-analyses and lead to discrepancies in results. [3] Such variations highlight the need for careful consideration of cohort characteristics when interpreting findings and underscore the importance of replication in varied populations to confirm and expand upon initial genetic associations.
Methodological and Statistical Constraints
Current genome-wide association studies (GWAS) often face methodological limitations that impact the scope and precision of identified genetic associations with ganglion thickness. A common practice is the exclusion of genetic variants with minor allele frequencies (MAF) below a certain threshold (e.g., <0.5% or <0.07%), which inherently omits possible rare variants that could have substantial effects on the trait. [4] Furthermore, the commercial genotyping arrays typically used in GWAS may not adequately cover rare variants, and even when exome sequencing is employed, the power to detect associations for rare or low-frequency variants is often limited to those with relatively large effect sizes. [5] This means that a significant portion of the genetic landscape, particularly rare variants, remains unexplored through these methods, necessitating more comprehensive sequencing approaches.
Another key challenge lies in the statistical power and interpretability of findings, especially concerning small effect sizes, which are common in complex traits like ganglion thickness. [5] Many studies, particularly imaging GWASs, may be underpowered to detect such small effects, hindering the discovery of all relevant genetic loci. [6] Additionally, the accurate measurement of phenotypes can be challenging or costly, potentially limiting the sample size and thus the power to detect associations, while phenotypic heterogeneity within the trait itself can further complicate genetic discovery. [5] Methodological inconsistencies, such as genotyping cohorts on different platforms in meta-analyses, can also introduce variability and impact the reliability of combined results. [3]
Elucidating Genetic Architecture and Clinical Translation
The interpretation of genetic associations for ganglion thickness is complicated by the intricate nature of complex traits, where identified SNPs may not represent the causal variants themselves but rather be in linkage disequilibrium with unanalyzed causal variants. [5] Genetic analyses often reveal that minor alleles can exhibit opposite effects across different genome-wide significant SNPs, and many GWAS SNPs demonstrate pleiotropic effects, influencing multiple traits, sometimes even antagonistically. [1] This complexity means that the genetic architecture of ganglion thickness is polygenic, involving numerous variants, and the individual contribution of each variant can be subtle and interconnected.
While GWAS serves as a foundational step in genetic investigation, bridging these findings to clinical utility requires extensive further research. A modest number of genetic variants identified through initial GWAS efforts suggests remaining knowledge gaps regarding the full genetic basis of ganglion thickness. [4] To achieve clinical applicability, it is crucial to move beyond mere association to consider the underlying genes, biological pathways, and the cumulative impact of polygenic risk, including the need for robust replication of findings in independent populations. [5] Future work must involve dense genotyping, expression studies, and functional translational research to fully elucidate the biological mechanisms and potential therapeutic targets related to ganglion thickness.
Variants
Genetic variations can significantly influence the structural properties of tissues, including ganglion thickness, by affecting cellular processes from development to maintenance. Several variants are implicated in pathways crucial for neuronal health and structural integrity. For instance, rs7503894 is located within or near _NPLOC4_, a gene whose variants, such as rs6565597, have been significantly associated with macular thickness and age-related macular degeneration (AMD). [1] This suggests a potential role for _NPLOC4_ in maintaining the structural integrity of the retina, including its ganglion cell layers. Similarly, the variant rs2008905 is associated with _PIK3C2A_, a gene belonging to the Phosphoinositide 3-kinase (PI3K) family, which is critical for regulating cell growth, survival, and differentiation. [4] Alterations in PI3K signaling can impact cellular proliferation and size, potentially influencing ganglion cell thickness. Furthermore, rs147136024 is linked to _CDH2_ (Cadherin 2), a cell adhesion molecule vital for establishing and maintaining cell-cell connections, particularly in the nervous system. [6] Variations in _CDH2_ could affect neuronal adhesion and the overall structural organization of ganglion cells, thereby influencing ganglion thickness.
Other variants exert their influence through the regulation of gene expression and cellular resilience pathways. The _MIR9-2HG_ gene, associated with rs17421627, hosts microRNA-9-2, a small non-coding RNA that plays a crucial role in the regulation of gene expression, especially during neurodevelopment and neuronal differentiation. [6] Changes in _miR-9_ activity due to rs17421627 could impact the development or maintenance of ganglion cells. Another key variant, rs9398171, is located near _FOXO3_, a transcription factor known for its involvement in stress resistance, metabolism, and cellular longevity. [4] _FOXO3_ helps cells respond to oxidative stress and promote survival, and variations like rs9398171 might influence the resilience and lifespan of ganglion cells, impacting their overall thickness. Additionally, rs182487621 is associated with _LINC00276_, a long intergenic non-coding RNA, which are emerging as significant regulators of gene expression, affecting various cellular processes including development and disease. [1] A variant in this lncRNA could modulate gene expression pathways critical for ganglion cell structure and thickness.
Metabolic and cell cycle pathways also play a critical role in determining ganglion thickness. The variant rs17279437 is associated with _SLC6A20_, a member of the solute carrier family, which facilitates the transport of specific molecules across cell membranes. [7] Efficient cellular transport is fundamental for neuronal function and nutrient supply, and variations in _SLC6A20_ could affect the metabolic health and structural integrity of ganglion cells. Furthermore, rs5442 is linked to _CDCA3_ and _GNB3_. _CDCA3_ is involved in cell cycle progression, which is vital for cell proliferation and tissue repair, while _GNB3_ plays a role in G-protein signaling pathways, regulating diverse cellular functions including growth and differentiation. [4] Polymorphisms like rs5442 could influence cell division rates or signaling cascades that are crucial for maintaining ganglion cell populations and size. Lastly, rs11762530 is associated with _ZNF619P1_ and _HMGN1P19_, genes potentially involved in chromatin remodeling and gene expression regulation, while rs10140252 is linked to _BBOF1_ and _ALDH6A1_, with _ALDH6A1_ being important for metabolic pathways like methylmalonate metabolism, which are crucial for neuronal energy and health. [7] Disruptions in these fundamental processes could indirectly affect the thickness of ganglion cell layers.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs7503894 | NPLOC4 | ganglion thickness retinal layer thickness retinal nerve fibre layer thickness |
| rs11762530 | ZNF619P1 - HMGN1P19 | retinal layer thickness ganglion thickness |
| rs17421627 | MIR9-2HG | eye measurement macula attribute macular telangiectasia type 2 retinal layer thickness ganglion thickness |
| rs17279437 | SLC6A20 | metabolite measurement brain connectivity attribute macula attribute macular telangiectasia type 2 brain attribute |
| rs9398171 | FOXO3 | schizophrenia lean body mass macula attribute retinal nerve fibre layer thickness retinal layer thickness |
| rs182487621 | LINC00276 | ganglion thickness |
| rs5442 | CDCA3, GNB3 | macula attribute Myopia retinal layer thickness ganglion thickness eye disease |
| rs10140252 | BBOF1, ALDH6A1 | retinal nerve fibre layer thickness retinal layer thickness ganglion thickness |
| rs2008905 | PIK3C2A | retinal layer thickness ganglion thickness schizophrenia |
| rs147136024 | PA2G4P3 - CDH2 | ganglion thickness |
Genetic and Epigenetic Regulation of Tissue Thickness
The thickness of biological tissues, including ganglia, is a complex trait influenced by a combination of genetic and epigenetic factors. Genome-wide association studies (GWAS) have been instrumental in identifying numerous genetic variants, primarily single nucleotide polymorphisms (SNPs), that are associated with variations in tissue thickness across various anatomical sites. [8] These identified variants, such as rs496547 and rs104948155, often reside within non-coding, regulatory regions of the genome, including enhancers and promoters, which are crucial for controlling the expression of target genes. [8] The functional consequence of these regulatory genetic variations is typically an alteration in gene expression levels, which in turn impacts the cellular processes that dictate tissue morphology and dimensions. [8]
Epigenetic modifications further modulate gene expression patterns critical for the development and maintenance of tissue thickness. Active enhancer regions, where many thickness-associated genetic variants are concentrated, are characterized by specific epigenetic markers such as H3K4me1 and H3K27ac histone modifications. [8] These marks, alongside DNase hypersensitivity, indicate accessible chromatin states that facilitate gene transcription, enabling the precise regulation of genes involved in fundamental cellular processes like proliferation, differentiation, and the production of extracellular matrix components, all of which are essential for tissue growth and structural integrity. Thus, the intricate interplay between an individual's genetic makeup and their epigenetic landscape ultimately orchestrates the molecular machinery that determines tissue thickness.
Molecular and Cellular Pathways
The regulation of tissue thickness is orchestrated by intricate molecular and cellular pathways that govern cell behavior and tissue architecture. Critical biomolecules, including a wide array of proteins, enzymes, receptors, and transcription factors, participate in signaling cascades that influence cell growth, survival, and matrix synthesis. For example, genes such as RUNX2, PIK3R1, and TGFA have been implicated in the regulation of cartilage thickness, illustrating how diverse molecular pathways, including endochondral differentiation and phosphoinositide-3-kinase signaling, contribute to tissue development and homeostasis. [8] Similarly, the WNT16 gene has been linked to cortical bone thickness and strength, underscoring the importance of WNT signaling in maintaining structural tissue integrity. [9]
These pathways coordinate various cellular functions, including cell-to-cell communication and responses to environmental stimuli, which are vital for maintaining the appropriate thickness of tissues. Disruptions in these signaling networks, whether stemming from genetic mutations or external factors, can lead to altered cellular functions, such as abnormal cell proliferation or compromised matrix synthesis, consequently affecting tissue dimensions. A precise balance within these molecular processes is indispensable for ensuring the structural and functional integrity of tissues, with broad implications for overall organ-level biology and systemic health.
Pathophysiological Processes and Homeostasis
Variations in tissue thickness frequently serve as indicators of underlying pathophysiological processes, encompassing a spectrum from developmental abnormalities to acquired diseases. For instance, altered cartilage thickness is a well-recognized feature of osteoarthritis (OA), a condition where homeostatic disruptions in cartilage metabolism lead to its degradation and subsequent changes in joint structure. [8] Similarly, changes in choroidal thickness are associated with specific ocular conditions like central serous chorioretinopathy, highlighting the direct link between tissue dimensions and disease mechanisms within the eye. [10]
These examples underscore how deviations from normal tissue thickness can profoundly impact organ function and overall physiological well-being. While the body often deploys compensatory responses to maintain homeostasis, prolonged or severe disruptions can result in irreversible tissue damage and impaired functional capacity. Understanding the genetic and molecular underpinnings of thickness variation provides crucial insights into disease susceptibility and can guide the development of potential therapeutic targets, emphasizing the critical importance of maintaining optimal tissue dimensions for health.
Transcriptional Regulation of Tissue Development
Genetic variants in regulatory regions play a crucial role in determining various tissue thicknesses by influencing gene expression. For instance, specific variants in linkage disequilibrium with rs496547 and rs104948155 are located in regulatory regions, suggesting their involvement in the transcriptional control of genes affecting tissue morphology. [4] One such mechanism involves long-range enhancers that regulate genes like RUNX2 during processes such as endochondral differentiation, potentially through a chromatin-loop mediating protein, thereby impacting cartilage thickness. [4] Similarly, the WNT16 gene has been identified to influence cortical bone thickness, indicating a broader role for Wnt signaling in the genetic regulation of bone mineral density and strength. [9] These examples highlight how precise transcriptional control, often mediated by distal regulatory elements, dictates the developmental trajectory and structural characteristics of tissues.
Cellular Signaling and Growth Pathways
Intracellular signaling cascades are fundamental to modulating cell growth, differentiation, and ultimately tissue thickness. The Phosphoinositide-3-Kinase (PI3K) pathway, with its regulatory subunit PIK3R1 as a strongly prioritized gene associated with rs10471753, represents a key mediator in cellular responses, often involved in processes like cell survival and proliferation. [4] Furthermore, the Wnt signaling pathways exert significant control over tissue development; the Wnt/calcium pathway, for example, activates NF-AT and influences cell fate, while Wnt-5a/Ca2+-induced NFAT activity can be counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1α signaling in various cell types, demonstrating complex feedback loops that fine-tune cellular responses and regulate cardiac hypertrophy. [11] Beyond these, G-protein signaling, integrated by regulators like RGS18 in platelets, plays a role in orchestrating diverse cellular functions by balancing activating and inhibitory signals, which can impact cell behavior and tissue dynamics. [12]
Cell Adhesion and Structural Integrity
The maintenance of tissue architecture and thickness is critically dependent on robust cell adhesion and the integrity of the cytoskeleton. Proteins such as MIM/MTSS1 are integral to this process, promoting actin assembly at intercellular junctions and being essential for the structural integrity of epithelial tissues. [11] This actin remodeling is vital for cell shape, motility, and tissue organization. Concurrently, E-cadherin-mediated cell-cell adhesion plays a significant role in maintaining the structural and functional integrity of epithelia, influencing how cells interact and form cohesive tissues. [5] Dysregulation in these adhesion mechanisms can lead to altered tissue morphology. Moreover, molecules like FAM5C can increase leukocyte adhesion molecules in vascular endothelial cells, contributing to vascular inflammation and potentially impacting the structural characteristics of the vascular wall. [13]
Metabolic and Ion Channel Regulation
Metabolic pathways and ion channel activity are deeply intertwined with cellular function and the overall regulation of tissue thickness. Transient receptor potential melastatin (TRPM) channels, specifically TRPM6 and TRPM7, are crucial for magnesium transport and play a significant role in vascular biology, with implications for conditions like hypertension. [14] The precise control of ion flux is essential for cell volume, signaling, and metabolic processes that support tissue growth and maintenance. Additionally, the galanin peptide family, acting through its receptors, exhibits pleiotropic biological actions that influence various physiological processes, including those potentially affecting cellular metabolism and growth in different tissues. [15] These interactions highlight how intricate metabolic and ion transport mechanisms contribute to the dynamic regulation of tissue homeostasis.
Disease-Relevant Mechanisms and Pathway Crosstalk
Dysregulation within these intricate pathways can underlie pathological changes in tissue thickness, often involving complex pathway crosstalk and network interactions. For instance, aberrant Wnt signaling, as seen in the interplay between Wnt-5a/Ca2+-induced NFAT activity and its counter-regulation by Wnt-5a/Yes-Cdc42-casein kinase 1α signaling, can contribute to conditions like cardiac hypertrophy. [11] Similarly, the involvement of FAM5C in increasing leukocyte adhesion molecules points to a role in vascular inflammation, a process that can alter vascular wall thickness. [13] Understanding these interactions, such as the influence of genetic variants on regulatory regions affecting genes like RUNX2 or PIK3R1 in cartilage development, offers insights into potential therapeutic targets for conditions characterized by abnormal tissue thickness. [4] These systems-level integrations and hierarchical regulations reveal emergent properties that define tissue health and disease.
Diagnostic and Risk Stratification Utility
Measurements of tissue thickness serve as crucial indicators for early disease detection and risk assessment across various physiological systems. For instance, common and internal carotid artery intima-media thickness (IMT) are established measures of subclinical atherosclerosis, providing valuable insight into an individual's cardiovascular risk profile, including the likelihood of myocardial infarction and stroke. [7] Similarly, the minimal joint space width (mJSW) in the hip joint, a proxy for cartilage thickness, is directly associated with hip osteoarthritis (OA), highlighting its utility in diagnosing and characterizing the structural changes indicative of joint degeneration. [4] In the context of ocular health, choroidal thickness measurements are instrumental in identifying conditions such as pachychoroid disease and central serous chorioretinopathy, where altered thickness is a key diagnostic feature. [10]
Furthermore, genetic associations with specific tissue thickness can refine risk stratification and lead to more personalized diagnostic approaches. For example, genetic variants near TGFA, PIK3R1, SLBP/FGFR3, TREH/DDX6, DOT1L, and SUPT3H/RUNX2 have been identified as influencing cartilage thickness and are also associated with hip OA, offering potential biomarkers for identifying individuals at higher risk for joint disease. [4] In patients with rheumatoid arthritis, a specific 3'UTR genetic variant of RARB has been linked to carotid IMT, suggesting its role in identifying those with increased cardiovascular risk within this inflammatory condition. [16] Such genetic insights, combined with physical measurements, enable clinicians to tailor screening and monitoring strategies to individuals based on their unique genetic predispositions and phenotypic expressions.
Prognostic Value and Disease Progression
Tissue thickness measurements hold significant prognostic value, aiding in the prediction of disease progression, treatment response, and long-term patient outcomes. Arterial IMT and calcification scores, for example, are powerful predictors of future cardiovascular morbidity and mortality, allowing for early intervention strategies in individuals with subclinical atherosclerosis. [7] The continuous nature of phenotypes like cartilage thickness, as measured by mJSW, offers a more sensitive indicator for monitoring the progression of joint diseases such as osteoarthritis, potentially revealing subtle changes before clinical symptoms become severe. [4] Understanding the genetic determinants of cartilage thickness can thus provide a deeper insight into the long-term trajectory of OA and its impact on joint health.
Moreover, genetic variants influencing cortical bone thickness, such as those related to WNT16, have been shown to impact bone mineral density, overall bone strength, and the risk of osteoporotic fractures. [9] These findings underscore the importance of thickness measurements as prognostic markers for skeletal health, guiding preventive measures and therapeutic decisions to mitigate fracture risk. By integrating these measurements with genetic information, clinicians can develop more accurate prognostic models and anticipate potential complications, leading to improved patient management and quality of life.
Therapeutic Targets and Personalized Approaches
The identification of genetic variants associated with tissue thickness opens new avenues for therapeutic development and personalized medicine. Novel genetic loci, such as TGFA, PIK3R1, FGFR3, and TREH, linked to cartilage thickness and hip OA, represent potential targets for future therapeutic interventions aimed at preserving joint health and preventing disease progression. [4] Differential expression of genes like TGFA, FGFR3, and PIK3R1 in OA cartilage lesions further supports their role in disease pathophysiology, suggesting that modulating their activity could offer therapeutic benefits. [4]
Personalized medicine approaches can leverage these genetic insights to tailor treatment selection and monitoring strategies. For instance, individuals carrying genetic variants associated with increased arterial IMT or calcification may benefit from more aggressive preventative measures or specific pharmacological interventions to reduce their cardiovascular risk. [7] Similarly, understanding an individual's genetic predisposition to variations in cartilage or bone thickness can inform personalized lifestyle recommendations, targeted exercise regimens, or early pharmacological treatments designed to maintain tissue integrity and function. This integration of genetic information with phenotypic thickness measurements allows for highly individualized patient care, moving beyond a one-size-fits-all approach to disease management.
Frequently Asked Questions About Ganglion Thickness
These questions address the most important and specific aspects of ganglion thickness based on current genetic research.
1. My parent had nerve issues; will my ganglion thickness be a problem too?
Yes, genetic factors are believed to play a role in determining ganglion thickness, influencing the number and size of nerve cells. So, if your parent had conditions related to ganglion size, you might have a genetic predisposition. However, environmental factors like injury or inflammation also contribute significantly.
2. Why do I get tingling, but my friend with the same job doesn't?
It could be due to a combination of genetic predispositions and individual environmental factors. Your genetic makeup might make your ganglia naturally more susceptible to changes in thickness, or your body might respond differently to the repetitive motions of your job. Even subtle differences in how your cells regulate growth can lead to variations.
3. I hurt my hand; could that change my ganglion thickness later?
Yes, an injury can definitely influence your ganglion thickness. Environmental factors like injury, inflammation, or disease processes are known to contribute to changes in ganglion size and morphology. An injury could lead to localized inflammation, potentially causing a temporary or even long-term increase in thickness.
4. Does ganglion thickness just change naturally as I get older?
The article doesn't directly state how ganglion thickness changes with normal aging. However, reduced thickness can be associated with neurodegenerative processes or nerve atrophy, which can sometimes be related to age-related conditions. It's a complex trait influenced by many factors, so individual changes vary.
5. Does my ethnic background affect my risk for ganglion issues?
Your ethnic background can play a role, as genetic studies have shown limitations in generalizability across different populations. Many analyses have been primarily conducted in specific ethnic groups, meaning that unique genetic variants or different effect sizes relevant to your background might not be fully understood yet. More diverse research is needed.
6. Can what I eat or how I exercise prevent ganglion problems?
While the article doesn't offer specific dietary or exercise advice directly impacting ganglion thickness, maintaining overall health is generally beneficial for your nervous system. Genetic predispositions interact with environmental factors, so a healthy lifestyle might help manage inflammatory responses or support nerve health, potentially mitigating some risks associated with ganglion issues.
7. Does my overall health or other diseases affect my ganglia?
Yes, absolutely. The biological basis of ganglion thickness is influenced by factors like disease processes. Conditions causing inflammation or affecting nerve health can lead to changes in ganglion size. For example, neurodegenerative processes could lead to reduced thickness, while certain diseases might cause enlargement.
8. Should I ask my doctor about ganglion thickness for my pain?
Yes, it's a valid question to discuss with your doctor, especially if you're experiencing pain, numbness, or tingling. Measuring ganglion thickness through imaging techniques can be a valuable diagnostic tool for clinicians to identify underlying neurological conditions or nerve compression that might be causing your symptoms.
9. Does stress really make my ganglia thicker or cause issues?
The article doesn't directly link stress to ganglion thickness. However, stress can contribute to inflammation in the body, and inflammation is mentioned as an environmental factor that can increase ganglion thickness. So, while not a direct cause, chronic stress might indirectly influence your nervous system's health and inflammatory responses.
10. Will my kids inherit my tendency for nerve compression problems?
There's a possibility, as genetic factors are believed to play a role in modulating the development and dimensions of ganglia. If you have a genetic predisposition to certain ganglion characteristics that increase nerve compression risk, your children could inherit some of those genetic influences. However, many factors contribute to such conditions.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Gao, X. R. et al. "Genome-wide association analyses identify 139 loci associated with macular thickness in the UK Biobank cohort." Hum Mol Genet, vol. 28, no. 8, 2018, pp. 1436-1452.
[2] Strawbridge, R. J., et al. "Carotid Intima-Media Thickness: Novel Loci, Sex-Specific Effects, and Genetic Correlations With Obesity and Glucometabolic Traits in UKB." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 40, no. 1, 2020, pp. 248–260.
[3] Szekely, E., et al. "Genetic associations with childhood brain growth, defined in two longitudinal cohorts." Genetic Epidemiology, vol. 42, no. 4, 2018, pp. 320–332.
[4] Castano-Betancourt MC, et al. "Novel Genetic Variants for Cartilage Thickness and Hip Osteoarthritis." PLoS Genet, vol. 12, no. 10, 2016, p. e1006356.
[5] Bis JC, et al. "Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque." Nat Genet, vol. 43, no. 10, 2011, pp. 940–6.
[6] Bi, X, et al. "Common genetic variants have associations with human cortical brain regions and risk of schizophrenia." Genet Epidemiol, 2019.
[7] O'Donnell, C. J., et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Med Genet, vol. 8, suppl. 1, 2007, p. S4.
[8] Castano-Betancourt, M. C., et al. "Novel Genetic Variants for Cartilage Thickness and Hip Osteoarthritis." PLoS Genetics, vol. 10, no. 10, 2014, e1004739.
[9] Zheng HF, et al. "WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk." PLoS Genet, vol. 8, no. 7, 2012, p. e1002742.
[10] Hosoda, Y. et al. "CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy." Proc Natl Acad Sci U S A, vol. 115, no. 24, 2018, pp. 6261-6266.
[11] Wild PS, et al. "Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function." J Clin Invest, vol. 127, no. 5, 2017, pp. 1759–72.
[12] Gegenbauer K, et al. "Regulator of G-protein signaling 18 integrates activating and inhibitory signaling in platelets." Blood, vol. 119, no. 16, 2012, pp. 3799–807.
[13] Sato J, et al. "Family with sequence similarity 5, member C (FAM5C) increases leukocyte adhesion molecules in vascular endothelial cells: implication in vascular inflammation." PLoS One, vol. 9, no. 9, 2014, p. e107236.
[14] Touyz RM. "Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension." Am J Physiol Heart Circ Physiol, vol. 294, no. 3, 2008, pp. H1103–18.
[15] Lang R, et al. "The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease." Pharmacology & therapeutics, vol. 115, no. 2, 2007, pp. 177–207.
[16] Lopez-Mejias, R., et al. "A genome-wide association study identifies a 3'UTR genetic variant of RARB associated with carotid intima-media thickness in rheumatoid arthritis." Arthritis Rheumatol, vol. 70, no. 12, 2018, pp. 1928-1936.